<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053698</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI209</org_study_id>
    <nct_id>NCT05053698</nct_id>
  </id_info>
  <brief_title>Evolution of Aqueous Flare in Rhegmatogenous Retinal Detachments Treated With Gas or Silicone Oil Tamponade.</brief_title>
  <acronym>FLADESIL</acronym>
  <official_title>Evolution of Aqueous Flare in Rhegmatogenous Retinal Detachments Treated With Gas or Silicone Oil Tamponade.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine and to compare the evolution of aqueous flare from presentation until the third&#xD;
      postoperative month in a series of consecutive patients who underwent primary vitrectomy for&#xD;
      rhegmatogenous retinal detachment (RRD), in 4 groups of patients :&#xD;
&#xD;
        -  Group 1 : 48 eyes primarily treated with gas tamponade&#xD;
&#xD;
        -  Group 2 : 11 eyes primarily treated with silicone oil tamponade&#xD;
&#xD;
        -  Sub-Group G1RG : 8 eyes among Group 1 treated with gas after relapse&#xD;
&#xD;
        -  Sub-Group G1RS : 3 eyes among Group 1 treated with silicone oil after relapse&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Actual">June 4, 2021</completion_date>
  <primary_completion_date type="Actual">June 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in aqueous flare measurement (expressed as photon counts per millisecond and measured with a laser flare-cell meter)</measure>
    <time_frame>preoperatively and postoperatively at 2 weeks and 3 months after surgery</time_frame>
    <description>Aqueous flare was measured preoperatively and postoperatively at 2 weeks, 4 weeks and 3 months with a laser flare-cell meter, in patients treated for RRD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in aqueous flare measurement (measured with a laser flare-cell meter)</measure>
    <time_frame>postoperatively at 2 weeks and 3 months after surgery</time_frame>
    <description>To describe the evolution of the aqueous humor flare between the postoperative visits at 2 weeks and at 3 months after retinal detachment surgery in each groups of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of aqueous flare values (measured with a laser flare-cell meter) between patients who relapsed and patients who didn't relapse</measure>
    <time_frame>preoperative</time_frame>
    <description>To compare the preoperative flare measurements between patients without versus with recurrence among those treated with gas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of measures of visual acuity</measure>
    <time_frame>preoperatively and postoperatively at 3 months</time_frame>
    <description>The best-corrected visual acuity (BCVA) was measured with projected-light Snellen charts and expressed in logMAR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of macular status</measure>
    <time_frame>preoperatively and postoperatively at 3 months</time_frame>
    <description>Evaluation of macular status with macular imaging by optical coherence tomography (Heidelberg Engineering)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapsing status (yes or not)</measure>
    <time_frame>at 3 months postoperative</time_frame>
    <description>Determined by careful fundus and peripheral retina examination.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Retinal Detachment</condition>
  <arm_group>
    <arm_group_label>Initial gas tamponade</arm_group_label>
    <description>Primary vitrectomy and fluid-air exchange with SF6 or C2F6 gas tamponade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initial silicone oil tamponade</arm_group_label>
    <description>Primary vitrectomy and fluid-air exchange with silicone oil tamponade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relapse treated with gas tamponade</arm_group_label>
    <description>Secondary vitrectomy and fluid-air exchange with SF6 or C2F6 or C3F8 gas tamponade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relapse treated with silicone oil tamponade</arm_group_label>
    <description>Secondary vitrectomy and fluid-air exchange with silicone oil tamponade</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aqueous flare measurement</intervention_name>
    <description>Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).</description>
    <arm_group_label>Initial gas tamponade</arm_group_label>
    <arm_group_label>Initial silicone oil tamponade</arm_group_label>
    <arm_group_label>Relapse treated with gas tamponade</arm_group_label>
    <arm_group_label>Relapse treated with silicone oil tamponade</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients addressed at the Ophthalmology Department for Rhegmatogenous Retinal&#xD;
        Detachment and who matched the inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients&#xD;
&#xD;
          -  patients who underwent surgery for rhegmatogenous retinal detachment (silicone or gas&#xD;
             tamponade)&#xD;
&#xD;
          -  aqueous flare measurement carried out preoperatively and postoperatively at 2-4 weeks&#xD;
             and 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetic retinopathy&#xD;
&#xD;
          -  glaucoma&#xD;
&#xD;
          -  non rhegmatogenous retinal detachment&#xD;
&#xD;
          -  active uveitis&#xD;
&#xD;
          -  pseudoexfoliation syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul BERROD, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BERROD Jean-Paul MD</name>
      <address>
        <city>Nancy</city>
        <state>Grand EST</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>BERROD Jean-Paul</investigator_full_name>
    <investigator_title>Professor BERROD Jean-Paul</investigator_title>
  </responsible_party>
  <keyword>Aqueous Flare</keyword>
  <keyword>Retinal Detachment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

